Webcast

TAAR1: More Than Just Another Receptor in Schizophrenia

Launch Date
10/23/2023
Credit Amount
0.5
Credit Expires
10/23/2024
This activity is part of a series

Faculty

Eric D. Achtyes, MD, MS, DFAPA
Professor and Chair, Department of Psychiatry
Western Michigan University Homer Stryker M.D. School of Medicine
Kalamazoo, MI
Eric D. Achtyes, MD, MS, DFAPA

Eric D. Achtyes, MD, MS graduated from Calvin University in Grand Rapids, Michigan and earned a master’s degree in chemistry from the University of Washington in Seattle, Washington. Dr. Achtyes completed medical school at the University of Michigan, his internship at the Michigan State University Kalamazoo Center for Medical Studies (MSU-KCMS) and his adult psychiatry residency training at Massachusetts General Hospital/McLean/Harvard program where he served as chief resident on the addictions inpatient unit at McLean Hospital. Following residency, Dr. Achtyes was an attending psychiatrist treating patients and conducting research at Pine Rest Christian Mental Health services for 15 years, serving as the Director of the Division of Psychiatry & Behavioral Medicine for the Michigan State University College of Human Medicine for 11 years and the Medical Director for Network180 for 9 years.  He is currently a Professor and Chair in the department of Psychiatry at the Western Michigan University Homer Stryker M.D. School of Medicine in Kalamazoo, Michigan where he teaches and mentors medical students and psychiatric residents.

Dr. Achtyes has been an investigator on more than fifty-five clinical trials in depression and schizophrenia, including both industry and federally funded research projects from the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and Centers for Medicare and Medicaid Services (CMS), and has authored more than 70 publications in peer-reviewed journals including the American Journal of Human Genetics, British Medical Journal, Journal of American Medical Association, Journal of American Medical Association Psychiatry, Molecular Psychiatry, and Nature Medicine. He is currently an Associate Editor for the journal Frontiers in Psychiatry.  Dr. Achtyes has served as the President of the Michigan Psychiatric Society and is a Distinguished Fellow of the American Psychiatric Association. In 2022 he was named ‘Physician/Psychiatrist of the Year’ by the National Alliance on Mental Illness (NAMI) Michigan.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Research on the role of trace amine-associated receptors, specifically TAAR1, in the pathophysiology of schizophrenia has led to investigational breakthroughs in novel treatments. Health care professionals (HCPs) may lack a comprehensive understanding of the therapeutic role of TAAR1 agonists and how they may be incorporated into the treatment of schizophrenia to optimize patient outcomes.

In the second installment of this three-part Journal Club series, TAAR1: More Than Just Another Receptor in Schizophrenia, expert faculty will present the latest information on how the research into the role that TAAR1 plays in schizophrenia is leading to emerging treatments targeting specific symptoms of schizophrenia, and how HCPs can utilize these novel therapies to optimize treatment plans.

Learning Objective

Identify the role of TAAR1 in schizophrenia to improve knowledge related to emerging therapies.

Financial Support

Supported in whole or in part by an educational grant from Sunovion and Otsuka.

Target Audience

Psychiatrists, nurse practitioners (NPs), physician associates (PAs), psychiatric nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-094-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Achtyes reports the following financial relationships:

Advisory Board: Alkermes, Indivior; Karuna Therapeutics; Otsuka America Pharmaceutical, Inc./Lundbeck; and Sunovion Pharmaceuticals Inc.

Consultant: Atheneum and Otsuka America Pharmaceutical, Inc./Lundbeck

Research Support: Alkermes; Biogen; Boehringer-Ingelheim; Johnson and Johnson; Karuna Therapeutics; Neurocrine Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc.

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Mary Gleason, PhD (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

JC-026-102323-90

TAAR1: More Than Just Another Receptor in Schizophrenia
Event Date: 10/23/2023
Register

Activities in the Series

Neuropsychiatric
11/07/2023

Targeting Domains of Schizophrenia with Individualized Therapy

0.5
Register Learn More
Neuropsychiatric
10/23/2023

TAAR1: More Than Just Another Receptor in Schizophrenia

0.5
Register Learn More